Skip to main content
. 2017 Feb 3;8(12):19803–19813. doi: 10.18632/oncotarget.15048

Table 2. T cell subset densities according to pre-treatment clinical and demographic factors.

Foxp3+ cell density CD8+ cell density CD3+ cell density
Lown (%) Highn (%) P Lown (%) Highn (%) P Lown (%) Highn (%) P
Age ≥ 65 24 (47) 27 (53) 0.560 24 (47) 27 (53) 0.560 20 (45) 24 (55) 0.353
< 65 29 (53) 26 (47) 29 (53) 26 (47) 27 (55) 22 (45)
Gender Male 44 (57) 33 (43) 0.017 44 (57) 33 (43) 0.017 36 (55) 30 (45) 0.227
Female 9 (31) 20 (69) 9 (31) 20 (69) 11 (41) 16 (59)
Distance from anal verge ≥ 7cm 28 (49) 29 (51) 0.846 28 (49) 29 (51) 0.846 25 (50) 25 (50) 0.911
< 7cm 25 (51) 24 (49) 25 (51) 24 (49) 22 (51) 21 (49)
Clinical T stage T2 4 (57) 3 (43) 0.246 2 (29) 5 (71) 0.395 1 (17) 5 (83) 0.207
T3 40 (47) 46 (53) 43 (50) 43 (50) 39(52) 36(48)
T4 8 (73) 3 (27) 7 (64) 4 (36) 6(60) 4(40)
Clinical N stage N0 14 (64) 8 (36) 0.150 12 (55) 10(45) 0.631 10 (48) 11 (52) 0.759
N1-2 38 (45) 44 (54) 40 (49) 42 (51) 36 (51) 34 (49)
Clinical M stage M0 47 (49) 48 (51) 0.742 47 (49) 48 (51) 0.975 41 (49) 43 (51) 0.714
M1-2 6 (60) 4 (40) 5 (50) 5 (50) 5 (63) 3 (37)

Bold text denotes significant associations (P < 0.05)